肺腺癌中HPRT1基因表达对患者总生存的影响

杨红秀; 朱中山

肺腺癌中HPRT1基因表达对患者总生存的影响

杨红秀,
朱中山^,

湖南省第二人民医院肿瘤科，湖南长沙　410007

基金项目: 湖南省自然科学基金科卫联合基金资助项目（2020JJ8080）。

详细信息

作者简介:
杨红秀（1975～），女，湖南怀化人，医学学士，副主任护师，主要从事肿瘤专业护理与科研工作

通讯作者:
朱中山，E-mail：84059616@qq.com

中图分类号: R734.2
计量
- 文章访问数: 12
- HTML全文浏览量: 9
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2024-04-02

Effect of HPRT1 Gene Expression on Overall Survival of Patients with Lung Adenocarcinoma

Hongxiu YANG,
Zhongshan ZHU^,

Dept. of Oncology，The 2nd People’s Hospital of Hunan Province，Changsha Hunan 410007，China

摘要

摘要: 目的探索HPRT1基因在肺腺癌中的表达特征、总生存率、功能激活以及免疫浸润中的影响。方法通过对TCGA肺腺癌数据以及多个GEO数据库中的肺腺癌数据进行挖掘分析。对比并验证HPRT1表达量与预后总生存（ overall surival，OS ）的关系，通过clusterProfiler分析HPRT1基因高表达组中上调基因的功能富集情况。且通过TIMER以及CIBERSORT算法计算肺腺癌中不同免疫细胞的浸润水平并对比在HPRT1高低表达组间的浸润程度差异。结果 HPRT1在肺腺癌组织中表达量显著上调，且在TCGA中证明HPRT1基因高表达的患者预后OS更差（P < 0.01）。经过2个GEO数据集的验证同样发现HPRT1基因高表达表现为预后OS更差（GSE13213，P < 0.01；GSE67639，P < 0.001）。差异分析显示高表达的患者中有683个基因的表达量显著上调且这些上调基因的功能主要富集与p53以及细胞周期等癌症相关的信号通路。TIMER以及CIBERSORT算法进行的免疫细胞浸润程度分析发现在高表达差预后人群中B细胞以及CD4T细胞含量均更低（P < 0.05）。结论 HPRT1基因表达量越高肺腺癌患者的总生存显著越差，且高表达患者的p53信号通路上调，B细胞以及CD4T细胞浸润程度显著下降。
- 肺腺癌 /
- HPRT1 /
- 总生存 /
- 数据挖掘
Abstract: Objective To explore the expression characteristics, prognostic effect, functional activation and immune infiltration of HPRT1 gene in lung adenocarcinoma. Methods The data of adenocarcinoma of the lung from TCGA and multiple GEO databases were collected and analyzed. The relationship between HPRT1 expression level and overall survival （OS） was compared and validated, and the functional enrichment of upregulated genes in the HPRT1 high-expression group was analyzed using ClusterProfiler. Furthermore, the infiltration levels of immune cells in lung adenocarcinoma were calculated using TIMER and CIBERSORT algorithms and compared between the HPRT1 high- and low-expression groups. Results The expression of HPRT1 was significantly upregulated in lung adenocarcinoma tissues, and TCGA dataset analysis showed the patients with high expression of HPRT1 gene had a poorer overall survival （OS） prognosis （P < 0.01）. Validation through two GEO datasets also shows that high expression of the HPRT1 gene is associated with a worse OS prognosis （GSE13213, P < 0.01, GSE67639, P < 0.001）. Differential analysis indicates that among patients with high expression, the expression levels of 683 genes are significantly upregulated, with these upregulated genes primarily enriched in signaling pathways related to cancer, such as p53 and the cell cycle. Analysis of immune cell infiltration levels using TIMER and CIBERSORT algorithms reveals that in the group with high expression and poor prognosis, the levels of B cells and CD4 T cells are lower （P < 0.05）. Conclusion The higher the expression level of the HPRT1 gene, the significantly worse the overall survival of patients with lung adenocarcinoma, and in patients with high expression levels, the p53 signaling pathway is upregulated, and the infiltration level of B cells and CD4T cells is significantly decreased.
- Lung Adenocarcinoma /
- HPRT1 /
- Overall Survival /
- Data Mining

HTML全文

图 1 HPRT1基因在肺腺癌样本中表达情况

A：HPRT1基因在肺腺癌组织与癌旁组织的差异；B：HPRT1基因表达量在患者肺腺癌不同分期样本中的对比；C：肺腺癌组织中HPRT1基因抗体（HPA006360）IHC定量表达。

Figure 1. HPRT1 gene expression in lung adenocarcinoma samples

下载: 全尺寸图片幻灯片

图 2 HPRT1基因表达与肺腺癌患者预后生存关系

A：TCGA肺腺癌数据集中HPRT1基因高表达与低表达生存曲线；B：多因素校正分析。

Figure 2. Relationship between HPRT1 gene expression and prognostic survival in patients with lung adenocarcinoma

下载: 全尺寸图片幻灯片

图 3 HPRT1基因表达与肺腺癌患者预后关系

A：GEO中多组数据集分析HPRT1基因在肺腺癌中的预后特征；B：GSE13213（左）以及GSE67639（右）验证HPRT1基因与预后OS的关系。

Figure 3. Relationship between HPRT1 gene expression and prognosis of lung adenocarcinoma patients

下载: 全尺寸图片幻灯片

图 4 高表达、低表达HPRT1基因之间功能分析

A：差异基因火山图；B：高表达的KEGG富集分析。

Figure 4. Functional enrichment analysis between high and low HPRT1 expression groups

下载: 全尺寸图片幻灯片

图 5 HPRT1高表达组免疫微环境特征分析

A：IMER算法分析HPRT1基因不同表达组间B细胞含量对比；B：TIMER算法分析HPRT1基因不同表达组间CD4T细胞含量对比；C：CIBERSORT算法验证HPRT1基因不同表达组间不同B细胞含量；D：CIBERSORT算法验证HPRT1基因不同表达组间不同T细胞含量。

Figure 5. Characterization of the immune microenvironment in the HPRT1 high expression group

下载: 全尺寸图片幻灯片

参考文献(20)

[1]	Tewari K S,Colombo N,Monk B J,et al. Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent,recurrent,or metastatic cervical cancer: Subgroup analyses from the KEYNOTE-826 randomized clinical trial[J]. JAMA Oncol,2024,10(2):185-192. doi: 10.1001/jamaoncol.2023.5410
[2]	Ma W,Zeng J,Montoya D J,et al. Labyrinthin expression is associated with poor prognosis in patients with non-small cell lung cancer[J]. Cancers (Basel),2023,15(3):924. doi: 10.3390/cancers15030924
[3]	Wang X S,Bai Y F,Verma V,et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer[J]. J Natl Cancer Inst,2023,115(6):742-748. doi: 10.1093/jnci/djac015
[4]	Chen F,Byrd A L,Liu J,et al. Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors[J]. Nat Commun,2023,14(1):336. doi: 10.1038/s41467-023-35784-x
[5]	John P,Sudandiradoss C. A comprehensive integrated gene network construction to explore the essential role of Notch 1 in lung adenocarcinoma (LUAD)[J]. J Biomol Struct Dyn,2024,1-13.
[6]	Xu H,Hu Y,Peng X,et al. Prediction of prognostic and immune therapy response in lung adenocarcinoma based on MHC-I-related genes[J]. Immunopharmacol Immunotoxicol,2024,46(1):93-106. doi: 10.1080/08923973.2023.2261146
[7]	Gurioli G,Conteduca V,Brighi N,et al. Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel[J]. BMC Med,2022,20(1):48. doi: 10.1186/s12916-022-02244-0
[8]	Miao J,Kang L,Lan T,et al. Identification of optimal reference genes in golden Syrian hamster with ethanol- and palmitoleic acid-induced acute pancreatitis using quantitative real-time polymerase chain reaction[J]. Animal Model Exp Med,2023,6(6):609-618. doi: 10.1002/ame2.12321
[9]	Chen L,He X,Yi S,et al. Six glycolysis-related genes as prognostic risk markers can predict the prognosis of patients with head and neck squamous cell carcinoma[J]. Biomed Res Int,2021,2021:8824195.
[10]	Gurioli G,Conteduca V,Brighi N,et al. Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel[J]. BMC Med,2022,20(1):48. doi: 10.1186/s12916-022-02244-0
[11]	Goldman M J,Craft B,Hastie M,et al. Visualizing and interpreting cancer genomics data via the Xena platform[J]. Nat Biotechnol,2020,38(6):675-678. doi: 10.1038/s41587-020-0546-8
[12]	Tomida S,Toshiyuki Takeuchi,Yukako Shimada,et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis[J]. J Clin Oncol,2009,27(17):2793-2799. doi: 10.1200/JCO.2008.19.7053
[13]	Gentles A J,Bratman S V,Diehn M,et al. Integrating tumor and stromal gene expression signatures with clinical indices for survival stratification of early-stage non-small cell lung cancer[J]. J Natl Cancer Inst,2015,107(10):djv211. doi: 10.1093/jnci/djv211
[14]	Uhlen M,Zhang C,Sunjae Lee,et al. A pathology atlas of the human cancer transcriptome[J]. Science,2017,357(6352):eaan2507. doi: 10.1126/science.aan2507
[15]	Yan Z,Wang Q,Zhendong Lu,et al. OSluca: An interactive web server to evaluate prognostic biomarkers for lung cancer[J]. Front Genet,2020,11:420. doi: 10.3389/fgene.2020.00420
[16]	Yu G,Wang L G,Yanyan Han,et al. clusterProfiler: An R package for comparing biological themes among gene clusters[J]. OMICS,2012,16(5):284-287. doi: 10.1089/omi.2011.0118
[17]	Wu M,Jiang L. Hydroxysteroid 17-beta dehydrogenase 6 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma[J]. Dig Dis Sci,2022,67(1):146-158. doi: 10.1007/s10620-021-06832-7
[18]	Chen B,Khodadoust M S,Liu C L,et al. Profiling tumor infiltrating immune cells with CIBERSORT[J]. Methods Mol Biol,2018,1711:243-259.
[19]	Mavridis K,Stravodimos K,Scorilas A. Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression[J]. Prostate,2013,73(11):1191-201. doi: 10.1002/pros.22667
[20]	朱中山,杨洲,江承川,等. 肺腺癌患者PLA2G1B表达情况与预后的相关性[J]. 昆明医科大学学报,2022,43(9):70-76.

相关文章(20)

[1]	杨晟强, 王平. ¹Hsp90抑制剂Ganetespib联合培美曲塞对肺腺癌细胞的影响, 昆明医科大学学报. 2024, 45(7): 1-12.
[2]	沈旺寻, 杨银煜, 李灿伟, 杨金荣, 伍思婧, 赵华君, 陀晓宇. ROR1在不同组织学分级浸润性肺腺癌中的表达与临床意义, 昆明医科大学学报. 2024, 45(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20240509
[3]	宋飞, 车佳音, 黄明, 徐丹, 李红阳, 李定坤, 向盈盈. 放射性¹²⁵I粒子在肺腺癌EMT及临床治疗中的作用, 昆明医科大学学报. 2023, 44(1): 140-143. doi: 10.12259/j.issn.2095-610X.S20230101
[4]	马诗淇, 丁毅, 李敏, 王梦慈, 张思宇, 冯树梅. LINC00341通过MAPK通路抑制肺腺癌细胞增殖, 昆明医科大学学报. 2023, 44(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20230403
[5]	刘邦卿, 李剑锋, 刘晓辉, 张劲男, 梁金屏. miR-196b靶向ERG促进肺腺癌的增殖和迁移, 昆明医科大学学报. 2023, 44(10): 83-91. doi: 10.12259/j.issn.2095-610X.S20231023
[6]	吴茂芳, 周永春, 蔡静静, 莫欣, 李瑛玮, 毛佳惠. 云南地区多结节肺腺癌EGFR突变及其临床意义, 昆明医科大学学报. 2022, 43(2): 60-66. doi: 10.12259/j.issn.2095-610X.S20220215
[7]	赵华君, 潘国庆, 唐莹, 王智园, 赵晓玮, 陀晓宇. ROR1在肺腺癌组织中的表达与气腔播散相关性, 昆明医科大学学报. 2022, 43(11): 22-29. doi: 10.12259/j.issn.2095-610X.S20221128
[8]	朱中山, 杨洲, 江承川, 李小兵, 任斗, 黄橙, 张维薇, 李湘军, 赵顺利. 肺腺癌患者PLA2G1B表达情况与预后的相关性, 昆明医科大学学报. 2022, 43(9): 70-76. doi: 10.12259/j.issn.2095-610X.S20220912
[9]	王应霞, 何琴, 王国芳, 张旋. 非小细胞肺癌中microRNA-21和EGFR的表达及意义, 昆明医科大学学报. 2021, 42(8): 101-105. doi: 10.12259/j.issn.2095-610X.S20210818
[10]	袁野, 常剑, 刘冬波, 姜保成. 混合型早期胃癌淋巴结转移情况及对预后的影响, 昆明医科大学学报. 2021, 42(3): 79-83. doi: 10.12259/j.issn.2095-610X.S20210321
[11]	段宏民, 陈楠, 杨永燕, 李云霞, 冯金象, 李航, 黄秀文, 吕东津, 张明, 赵玉涛. 安罗替尼对肺腺癌细胞株A549放射敏感性的影响及机制, 昆明医科大学学报. 2021, 42(8): 40-46. doi: 10.12259/j.issn.2095-610X.S20210808
[12]	马燕粉, 胡建, 张宁, 武倩, 王晓琴. 肺腺癌性与结核性胸腔积液患者凝血指标变化及异常模式, 昆明医科大学学报. 2021, 42(10): 145-150. doi: 10.12259/j.issn.2095-610X.S20211021
[13]	马国玉, 熊庆, 蒋国庆, 杨家甜, 木云珍. 基于生物信息学方法识别肺腺癌预后相关基因, 昆明医科大学学报. 2020, 41(07): 30-37.
[14]	吴琪燕, 边革元, 程绘珺, 李娇霞, 王书廷, 黄照略. 肺腺癌预后因素及血清肿瘤标记物的诊断效能, 昆明医科大学学报. 2020, 41(09): 32-37.
[15]	王吉妍, 段勇. 基于数据挖掘对冠心病诊断的研究进展, 昆明医科大学学报. 2018, 39(12): 1-4.
[16]	朱中山, 严文辉, 李小兵, 杨洲, 白鹏. 200例肺腺癌脑转移患者驱动基因突变情况及预后关系, 昆明医科大学学报. 2018, 39(08): 47-50.
[17]	王家祝, 刁先民, 康真, 常润生, 雷子发, 孙黎, 王兆敏, 曹娥, 李文辉. 云南个旧锡矿工人职业相关肺癌病理变化及97例鳞癌治疗与生存, 昆明医科大学学报. 2017, 38(04): 52-57.
[18]	王华. 吉非替尼治疗晚期肺腺癌临床观察, 昆明医科大学学报. 2014, 35(04): -.
[19]	. 宣威肺腺癌xwlc-05和肺腺癌A549细胞株体外培养细胞活力的比较研究, 昆明医科大学学报. 2011, 32(07): -.
[20]	. 肺腺癌A549细胞中Nestin的表达, 昆明医科大学学报. 2011, 32(08): -.